Show simple item record

dc.contributor.authorMansoori, B
dc.contributor.authorMohammadi, A
dc.contributor.authorDavudian, S
dc.contributor.authorShirjang, S
dc.contributor.authorBaradaran, B
dc.date.accessioned2018-08-26T04:56:06Z
dc.date.available2018-08-26T04:56:06Z
dc.date.issued2017
dc.identifier10.15171/apb.2017.041
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/38444
dc.description.abstractAnticancer drugs resistance is a complex process that arises from altering in the drug targets. Advances in the DNA microarray, proteomics technology and the development of targeted therapies provide the new strategies to overcome the drug resistance. Although a design of the new chemotherapy agents is growing quickly, effective chemotherapy agent has not been discovered against the advanced stage of cancer (such as invasion and metastasis). The cancer cell resistance against the anticancer agents can be due to many factors such as the individual's genetic differences, especially in tumoral somatic cells. Also, the cancer drug resistance is acquired, the drug resistance can be occurred by different mechanisms, including multi-drug resistance, cell death inhibiting (apoptosis suppression), altering in the drug metabolism, epigenetic and drug targets, enhancing DNA repair and gene amplification. In this review, we outlined the mechanisms of cancer drug resistance and in following, the treatment failures by common chemotherapy agents in the different type of cancers.
dc.language.isoEnglish
dc.relation.ispartofAdvanced pharmaceutical bulletin
dc.titleThe Different Mechanisms of Cancer Drug Resistance: A Brief Review.
dc.typearticle
dc.citation.volume7
dc.citation.issue3
dc.citation.spage339
dc.citation.epage348
dc.citation.indexPubmed
dc.identifier.DOIhttps://doi.org/10.15171/apb.2017.041


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record